Rate My Professor Phillip Bergen

Bergen's research centers on the pharmacokinetics and pharmacodynamics of antibiotics, with a focus on optimizing dosing and combination therapies for polymyxins such as colistin, fosfomycin, and others against multidrug-resistant Gram-negative bacteria, including Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae. His studies address antimicrobial resistance mechanisms, phage resistance, neurotoxicity, and population pharmacokinetics in clinical settings. Key publications include 'Dosing of colistin - back to basic PK/PD' (2012), 'In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa' (2015, Journal of Antimicrobial Chemotherapy), 'Clinically relevant concentrations of fosfomycin combined with colistin and/or doripenem display synergistic killing and optimised pharmacodynamics in multidrug-resistant Pseudomonas aeruginosa' (2016, Journal of Antimicrobial Chemotherapy), 'Model-Informed Dose Optimisation of Polymyxin-Rifampicin Combination Therapy Against Carbapenem-Resistant Acinetobacter baumannii' (2023), 'Population Pharmacokinetics of Nebulized Polymyxin B in Epithelial Lining Fluid of Critically Ill Patients' (2025), and 'Phage Resistance Bidirectionally Altered Antibiotic Susceptibility in Klebsiella pneumoniae via galE mutation' (2026). With 94 publications cited over 3700 times, his work significantly influences strategies for treating infections caused by superbugs.